Alexion Provides Update on Recall of Two Soliris Lots; Says No Effect on FY14 Outlook
December 13, 2013 at 16:01 PM EST
Alexion Pharmaceuticals (NASDAQ: ALXN ) today is providing further information regarding a previously communicated voluntary recall of two lots of Soliris® (eculizumab) Concentrated Solution for Intravenous Infusion. As stated on Nov. 12, 2013, the two lots were found to contain visible particles. At that time, Alexion provided instructions to return any unused vials